XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Brokerages

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $53.75.

Several equities analysts have recently issued reports on XOMA shares. Benchmark cut XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a research note on Thursday, April 30th.

XOMA Royalty Stock Performance

NASDAQ:XOMA opened at $40.17 on Tuesday. XOMA Royalty has a 12-month low of $22.29 and a 12-month high of $45.22. The firm has a market cap of $503.77 million, a PE ratio of 25.59 and a beta of 0.86. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96. The stock has a fifty day moving average price of $41.31 and a 200 day moving average price of $36.16.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. Sell-side analysts anticipate that XOMA Royalty will post 0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of XOMA Royalty by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after purchasing an additional 29,298 shares during the last quarter. Opaleye Management Inc. increased its holdings in XOMA Royalty by 14.7% in the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after buying an additional 37,503 shares during the last quarter. Geode Capital Management LLC increased its holdings in XOMA Royalty by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock valued at $5,893,000 after buying an additional 9,589 shares during the last quarter. Woodline Partners LP raised its stake in XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after buying an additional 29,715 shares in the last quarter. Finally, State Street Corp raised its stake in XOMA Royalty by 4.7% in the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after buying an additional 7,873 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.